View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 3, 2021updated 11 Jul 2022 2:16pm

ARCA biopharma completes enrolment in Phase IIb Covid-19 therapy trial

The trial will assess two dose levels of the small recombinant protein versus heparin in hospitalised Covid-19 patients.

ARCA biopharma has completed participants enrolment in the Phase IIb ASPEN-COVID-19 clinical trial of its small recombinant protein, rNAPc2, to treat hospitalised patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The latest move comes after the receipt of Argentina and Brazil’s regulatory agencies approval in July 2021 to begin enrolment in the countries.

The global, multi-centre, randomised clinical trial has enrolled 160 participants at clinical investigative sites in Argentina, Brazil, and the US.

It will assess two dose levels of the small recombinant protein versus heparin in hospitalised Covid-19 patients with a high D-dimer level.

A biomarker, D-dimer is usually used for coagulation activation assessment, which is related to adverse clinical outcomes.

It is observed to be high in 40% to 75% of hospitalised Covid-19 patients.

The D-dimer level change from baseline to day eight on receiving rNAPc2 compared to heparin will be the primary goal of the study.

Determining the optimal rNAPc2 dose regimen for a potential Phase III clinical trial and assessment of safety will be some of the other goals of the clinical trial.

ARCA biopharma president and CEO Dr Michael Bristow said: “Completing enrolment in ASPEN-Covid-19 is a significant milestone for the development of rNAPc2 as a potential treatment option for patients hospitalised with Covid-19 who have biomarker evidence of coagulopathy.

“We are grateful to the patients, their families, investigators and clinical research sites that are participating in the trial. We look forward to sharing the top-line trial results in the first quarter of next year and reviewing the findings with the FDA.”

rNAPc2 has been designed to selectively block tissue factors (TF). It is being developed as a potential therapy for Covid-19, as well as other viral diseases.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena